Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.

NCT02180763 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02180763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02180763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.
Lead sponsor
Octapharma
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2014
Completion date
August 26, 2017
Enrollment
31 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency (pid)